Navigation Links
Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
Date:1/4/2012

BEIJING, Jan. 4, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced the resignation of Ms. Chup Hung Mok from its Board of Directors for personal reasons.  The Board has commenced a search for a replacement director and is considering a few candidates.  Sinovac will make the appropriate announcement in due course when it appoints a new director.

Dr. Weidong Yin, Chairman and CEO, stated, “We would like to thank Cathy for her significant contributions over the past six years as a director.  We appreciate the efforts she made to the enhancement of our corporate governance, performance evaluation, financial operations and strategy execution.”

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), pneumococcal polysaccharides, human rabies, HIB, rotavirus and epidemic meningitis, chickenpox and mumps & rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, and has launched its internally developed inactivated rabies vaccine in China.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9871/9659
Fax:  +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel:  +1-646-536-7017
Email: scarrington@theruthgroup.com

Media
Victoria Aguiar
The Ruth Group
Tel:  +1-646-536-7013
Email:  vaguiar@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac to Participate in Four Investor Conferences in September 2011
2. Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results
3. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
4. Sinovac Participates in Two Investor Conferences in November
5. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
6. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
7. Sinovac Reports Unaudited First Quarter 2010 Financial Results
8. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
9. Sinovac Announces Upsizing and Pricing of Common Share Offering
10. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
11. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/19/2020)... , ... March 17, 2020 ... ... supply and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, ... for ovarian cancer and other solid tumor indications. The collaboration will leverage ...
(Date:3/10/2020)... (PRWEB) , ... March 10, 2020 , ... Ortho Clinical ... through innovative laboratory solutions, announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen ... transfusion, is cleared to run on ORTHO VISION® and ORTHO VISION® Max in the ...
(Date:3/4/2020)... ... ... This month, Cognosante will make its annual appearance at the HIMSS Global Health Conference ... that align with the HIMSS annual theme, “Be the Change.” , Cognosante’s presence ... From Interoperability and HIE to Cloud Computing and BPO ...
(Date:2/28/2020)... ... February 26, 2020 , ... Designed primarily for laboratory and ... dedicated controller, thus simplifying setup, streamlining integration, and optimizing workflow. Capable of recording ... Fastec Imaging’s new HS Series cameras to be released. The HS Series includes ...
Breaking Biology Technology:
(Date:3/11/2020)... ... March 11, 2020 , ... ... backed by Siemens Healthineers and several healthcare VC firms introduces a first of ... in over 100 countries and has caused over 4,000 fatalities to date. Over ...
(Date:3/9/2020)... , ... March 09, 2020 ... ... witnessed a steep growth rate of 64% last year, as enterprises sought ... research from Everest Group. Unfortunately, only 13% of all transformation efforts delivered ...
(Date:3/5/2020)... ... ... Patients in need of new teeth after tooth extraction or full mouth ... of Ocala. Same-day dental implants allow patients with an entire mouth of ... This treatment utilizes advanced technology and Dr. Brand’s unique experience and skills to provide ...
Breaking Biology News(10 mins):